Jazz Pharmaceuticals plc
JAZZ
$229.63
$0.440.19%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 1.07B | 1.20B | 1.13B | 1.05B | 897.80M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.07B | 1.20B | 1.13B | 1.05B | 897.80M |
| Cost of Revenue | 96.60M | 112.92M | 128.88M | 116.27M | 74.70M |
| Gross Profit | 972.30M | 1.09B | 997.23M | 929.44M | 823.10M |
| SG&A Expenses | 352.70M | 418.46M | 379.15M | 358.40M | 514.00M |
| Depreciation & Amortization | 172.30M | 169.74M | 168.37M | 162.10M | 154.40M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 817.60M | 873.79M | 874.60M | 826.74M | 923.80M |
| Operating Income | 251.30M | 324.14M | 251.51M | 218.97M | -26.00M |
| Income Before Tax | 299.20M | 208.41M | 8.99M | -735.64M | -110.30M |
| Income Tax Expenses | 6.10M | 4.96M | -242.42M | -17.17M | -17.80M |
| Earnings from Continuing Operations | 293.10M | 203.45M | 251.41M | -718.47M | -92.50M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 293.10M | 203.45M | 251.41M | -718.47M | -92.50M |
| EBIT | 251.30M | 324.14M | 251.51M | 218.97M | -26.00M |
| EBITDA | 432.70M | 503.31M | 429.76M | 392.98M | 138.80M |
| EPS Basic | 4.74 | 3.33 | 4.14 | -11.74 | -1.52 |
| Normalized Basic EPS | 3.40 | 2.85 | 2.09 | 1.73 | -0.82 |
| EPS Diluted | 4.43 | 3.21 | 4.08 | -11.74 | -1.52 |
| Normalized Diluted EPS | 3.18 | 2.74 | 2.06 | 1.73 | -0.82 |
| Average Basic Shares Outstanding | 61.90M | 61.06M | 60.70M | 61.19M | 61.00M |
| Average Diluted Shares Outstanding | 66.10M | 63.43M | 61.61M | 61.19M | 61.00M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |